ASH 2020
Convalescent plasma therapy may “potentiate the increased thrombotic risk and endotheliopathy” thought to contribute to disease pathophysiology in COVID-19.
CHEST 2020
Pulmonary hypertension is associated with higher in-hospital mortality, morbidity, length of stay, and health care utilization in patients admitted to the hospital with an acute exacerbation of COPD.
CHEST 2020
Chronic obstructive pulmonary disease may be associated with higher rates of mortality in patients with coronavirus disease 2019.
CHEST 2020
Hospitalized patients with severe COVID-19 and diabetes are less likely to be discharged from the hospital and are more likely to experience in-hospital mortality compared with patients without diabetes.
CHEST 2020
The MuLBSTA score accurately predicted outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia.
CHEST 2020
Among lung transplant recipients, tacrolimus compared to cyclosporine may be associated with decreased incidence of bronchiolitis obliterans syndrome and number of acute rejection episodes.
ATS Virtual Program 2020
Treatment with LIQ861, an inhaled dry-powder form of treprostinil, was associated with significant improvements in several clinical and quality of life measures in patients with pulmonary arterial hypertension.
ATS 2020
Inhaled nitric oxide 45 mcg/kg of ideal body weight per hour was effective for improving physical activity in patients at risk for pulmonary hypertension associated with fibrotic interstitial lung disease.
ACR 2019, News
Tildrakizumab-asmn demonstrated significant improvements to swollen and tender joint counts and pain in patients with active psoriatic arthritis (PsA), according to phase 2b interim results.
CHEST 2019
Combination therapy consisting of once-daily macitentan and tadalafil was associated with reductions in pulmonary vascular resistance in patients with pulmonary arterial hypertension.
